232 related articles for article (PubMed ID: 32668023)
1. Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta-analysis.
Forbes RB; McCarron M; Cardwell CR
Headache; 2020 Sep; 60(8):1542-1557. PubMed ID: 32668023
[TBL] [Abstract][Full Text] [Related]
2. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
[TBL] [Abstract][Full Text] [Related]
3. Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis.
Kokoti L; Drellia K; Papadopoulos D; Mitsikostas DD
J Neurol; 2020 Apr; 267(4):1158-1170. PubMed ID: 31919565
[TBL] [Abstract][Full Text] [Related]
4. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.
Hong P; Wu X; Liu Y
Clin Neurol Neurosurg; 2017 Mar; 154():74-78. PubMed ID: 28129635
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
[TBL] [Abstract][Full Text] [Related]
6. Meta-regression to explain the placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention.
Regnier SA; Lee XY
J Med Econ; 2023; 26(1):1072-1080. PubMed ID: 37594778
[No Abstract] [Full Text] [Related]
7. CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis.
Han L; Liu Y; Xiong H; Hong P
Brain Behav; 2019 Feb; 9(2):e01215. PubMed ID: 30656853
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis.
Deng H; Li GG; Nie H; Feng YY; Guo GY; Guo WL; Tang ZP
BMC Neurol; 2020 Feb; 20(1):57. PubMed ID: 32061264
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
Nahas SJ; Naegel S; Cohen JM; Ning X; Janka L; Campos VR; Krasenbaum LJ; Holle-Lee D; Kudrow D; Lampl C
J Headache Pain; 2021 Nov; 22(1):141. PubMed ID: 34819017
[TBL] [Abstract][Full Text] [Related]
11. Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials.
Robblee J; Hakim SM; Reynolds JM; Monteith TS; Zhang N; Barad M
Headache; 2024 May; 64(5):547-572. PubMed ID: 38634515
[TBL] [Abstract][Full Text] [Related]
12. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies.
Nsaka M; Scheffler A; Wurthmann S; Schenk H; Kleinschnitz C; Glas M; Holle D
Brain Behav; 2022 Jul; 12(7):e2662. PubMed ID: 35687795
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.
Sun H; Dodick DW; Silberstein S; Goadsby PJ; Reuter U; Ashina M; Saper J; Cady R; Chon Y; Dietrich J; Lenz R
Lancet Neurol; 2016 Apr; 15(4):382-90. PubMed ID: 26879279
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin Gene-Related Peptide Monoclonal Antibody Use for the Preventive Treatment of Refractory Headache Disorders in Adolescents.
Greene KA; Gentile CP; Szperka CL; Yonker M; Gelfand AA; Grimes B; Irwin SL
Pediatr Neurol; 2021 Jan; 114():62-67. PubMed ID: 33232919
[TBL] [Abstract][Full Text] [Related]
15. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
Silberstein SD; Cohen JM; Yang R; Gandhi SK; Du E; Jann AE; Marmura MJ
J Headache Pain; 2021 Jan; 22(1):2. PubMed ID: 33413075
[TBL] [Abstract][Full Text] [Related]
16. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
[TBL] [Abstract][Full Text] [Related]
17. The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis.
Fernández-Bravo-Rodrigo J; Pascual-Morena C; Flor-García A; Saz-Lara A; Sequí-Dominguez I; Álvarez-Bueno C; Barreda-Hernández D; Cavero-Redondo I
Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162776
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Sakai F; Suzuki N; Kim BK; Tatsuoka Y; Imai N; Ning X; Ishida M; Nagano K; Iba K; Kondo H; Koga N
Headache; 2021 Jul; 61(7):1102-1111. PubMed ID: 34323290
[TBL] [Abstract][Full Text] [Related]
19. CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine.
Israel H; Neeb L; Reuter U
Curr Pain Headache Rep; 2018 Apr; 22(5):38. PubMed ID: 29623520
[TBL] [Abstract][Full Text] [Related]
20. Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
Ashina M; Cohen JM; Gandhi SK; Du E
Headache; 2021 Jun; 61(6):916-926. PubMed ID: 34115380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
